Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taking a Bayesian route to the Triple Crown

This article was originally published in The Gray Sheet

Executive Summary

"If you have a prior set of events of eight positive outcomes and zero negative outcomes, and you have an increasing effect as demonstrated by a win of 11 and one-half lengths at Pimlico, what is the likelihood of Smarty Jones winning the Triple Crown?" John Sladky, MD, Emory University, asks attendees at an FDA/Johns Hopkins University-sponsored symposium on Bayesian statistical analysis May 21. For coverage of how Bayesian approaches can enhance medical device clinical studies, see story: 1CDRH Promotes Bayesian Tool To Speed Approvals; Statistical Rigor Required...

You may also be interested in...



CDRH Promotes Bayesian Tool To Speed Approvals; Statistical Rigor Required

FDA is encouraging medical device firms to consider using Bayesian estimation in clinical trials to streamline regulatory timeframes

COVID-19: Test Developers Focus On New Variants

Researchers discussed ways to ensure COVID-19 diagnostics work for all variants during a recent webinar.

Amunix Raises $117m To Take Novel T-Cell Engager Into The Clinic

Amunix’s XTEN technology for half-life extension and precise drug delivery has been used by multiple partners over the past 15 years, but now the firm is building its own cancer therapy pipeline.

UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel